Join to View Full Profile
2400 Pratt StDurham, NC 27705
Phone+1 919-684-8964
Dr. Lin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Chenyu Lin, MD, based in Durham, NC, specializes in oncology with a subspecialty in hematologic oncology. He completed his medical education at the University of Chicago Pritzker School of Medicine in 2016, followed by an internal medicine residency at McGaw Medical Center of Northwestern University and a fellowship in hematology and medical oncology at Duke University Hospital. Dr. Lin is currently a staff physician at Durham Veterans Affairs Medical Center and an assistant professor at Duke University. His recent research includes publications in notable journals such as Blood Advances and the Journal of Clinical Oncology, focusing on treatments and outcomes in hematologic malignancies.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2020 - 2023
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2016 - 2019
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2016, M.D.
Yale UniversityB.S., Molecular Biophysics & Biochemistry, 2008 - 2012
Certifications & Licensure
NC State Medical License 2023 - 2026
IL State Medical License 2016 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.Matthew A Bergens, Yen P Lowder, Yan Li, Ernaya J Johnson, Hilary M Winthrop
Bone Marrow Transplantation. 2025-04-12 - 3 citationsOutcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2025-02-10 - 2 citationsSiltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14
Press Mentions
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health EquityApril 25th, 2022- Gamida Cell Announces Data to Be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsJanuary 7th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
